Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
George Cardoza is Chief Financial Officer at Sophia Genetics. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 9, 2026, each linked to the official Form 4.
Chief Financial Officer
Disclosures on record
1
Companies involved
1
1 buy, median +54.7 pts vs S&P 500, beat it 1 of 1 time.
Average +54.7 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Jun 6, 2026 to Jun 6, 2026, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 100% of the 1 measured at 90 days finished ahead of the index. $1,000 placed after each of the 2 purchases disclosed since 2025-11-14 would be worth $2.6K today ($2K put in); the same in the S&P 500 (SPY): $2K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. ·
Sophia GeneticsSOPH
Nov 6, 2026Bought~$141Kdisclosed Nov 9
DetailsOfficial recordAs of the latest filing on , George Cardoza reported holding 326,726 shares of Sophia Genetics (SOPH), worth about $2.68M at the last close of $8 (Nov 13, 2026). In the last 12 months, George Cardoza bought $141K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Sophia Genetics SOPH | 326,726 | 327K direct | $8 | $2.68M | Nov 6, 2026 |
Is this George Cardoza’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
George Cardoza bought shares on the open market in 2011, 2012 and 2026 across 2 companies. Sales in 6 of the 16 years since 2011.
George Cardoza reported 3 open-market purchases and 12 sales since 2011; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $141K1×1 trade | — |
| 2021 | — | $8.08M2×2 trades |
| 2020 | — | $9.14M3×3 trades |
| 2019 | — | $5.18M4×4 trades |
| 2016 | — | $219K1×1 trade |
| 2014 | — | $257K1×1 trade |
| 2013 | — | $73K1×1 trade |
| 2012 | $6.6K1×1 trade | — |
| 2011 | $3.6K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 6, 2026, George Cardoza reported holding 326,726 shares of Sophia Genetics (SOPH). At the last close of $8 on Nov 13, 2026, that is about $2.68M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, George Cardoza reported 1 open-market purchase worth $141K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
George Cardoza bought shares on the open market in 2011, 2012 and 2026 across 2 companies. Sales in 6 of the 16 years since 2011.
In SEC filings since 2011: the latest open-market purchase is from 2026; the latest open-market sale is from 2021.
2 companies: Sophia Genetics (SOPH, 2026), NeoGenomics Laboratories, Inc. (NEO, 2011–2021).
George Cardoza reported 2 open-market purchases and 12 sales here, 2011 to 2021.
George Cardoza reported 1 open-market purchase and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
